Blood filter during heart bypass may prevent organ damage, but trial stopped early

NCT ID NCT06659289

Terminated Disease control Sponsor: Efferon JSC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a device called Efferon LPS that filters blood during heart surgery when a heart-lung machine is used. The goal was to see if it could prevent multiple organ failure, especially kidney damage. Only 14 people took part before the study was stopped, so the results are not reliable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efferon LPS hemoperfusion device
What this could lead to: If it works, this device could reduce the risk of organ failure and kidney damage after heart surgery.
What could go wrong: The trial was terminated early with only 14 participants, so results are very limited. It is unclear if the device provides any real benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart disorder acute kidney injury prevention target multiple organ dysfunction syndrome prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC DISEASE MULTIPLE ORGAN DYSFUNCTION SYNDROME

Contacts and locations

Locations

Pavlov First Saint Petersburg State Medical University

Saint Petersburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.